JP4942485B2 - Ｆｉｓｃｈｅｒ−ｆｉｎｋ型合成および続くアシル化による４，５−ジアルキル−３−アシル−ピロール−２−カルボン酸誘導体の製造 - Google Patents

Ｆｉｓｃｈｅｒ−ｆｉｎｋ型合成および続くアシル化による４，５−ジアルキル−３−アシル−ピロール−２−カルボン酸誘導体の製造 Download PDF

Info

Publication number
JP4942485B2
JP4942485B2 JP2006538556A JP2006538556A JP4942485B2 JP 4942485 B2 JP4942485 B2 JP 4942485B2 JP 2006538556 A JP2006538556 A JP 2006538556A JP 2006538556 A JP2006538556 A JP 2006538556A JP 4942485 B2 JP4942485 B2 JP 4942485B2
Authority
JP
Japan
Prior art keywords
compound
formula
alkyl
note
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006538556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509991A5 (enExample
JP2007509991A (ja
Inventor
マイケル・ウォレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2007509991A publication Critical patent/JP2007509991A/ja
Publication of JP2007509991A5 publication Critical patent/JP2007509991A5/ja
Application granted granted Critical
Publication of JP4942485B2 publication Critical patent/JP4942485B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006538556A 2003-10-28 2004-10-28 Ｆｉｓｃｈｅｒ−ｆｉｎｋ型合成および続くアシル化による４，５−ジアルキル−３−アシル−ピロール−２−カルボン酸誘導体の製造 Expired - Fee Related JP4942485B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51528303P 2003-10-28 2003-10-28
US60/515,283 2003-10-28
PCT/US2004/037985 WO2005042484A1 (en) 2003-10-28 2004-10-28 Preparation of 4,5-dialkyl-3-acyl-pyrrole-2-carboxylic acid derivatives by fischer-fink type synthesis and subsequent acylation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011131818A Division JP2011231117A (ja) 2003-10-28 2011-06-14 Ｆｉｓｃｈｅｒ−ｆｉｎｋ型合成および続くアシル化による４，５−ジアルキル−３−アシル−ピロール−２−カルボン酸誘導体の製造

Publications (3)

Publication Number Publication Date
JP2007509991A JP2007509991A (ja) 2007-04-19
JP2007509991A5 JP2007509991A5 (enExample) 2009-06-25
JP4942485B2 true JP4942485B2 (ja) 2012-05-30

Family

ID=34549387

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006538556A Expired - Fee Related JP4942485B2 (ja) 2003-10-28 2004-10-28 Ｆｉｓｃｈｅｒ−ｆｉｎｋ型合成および続くアシル化による４，５−ジアルキル−３−アシル−ピロール−２−カルボン酸誘導体の製造
JP2011131818A Pending JP2011231117A (ja) 2003-10-28 2011-06-14 Ｆｉｓｃｈｅｒ−ｆｉｎｋ型合成および続くアシル化による４，５−ジアルキル−３−アシル−ピロール−２−カルボン酸誘導体の製造

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011131818A Pending JP2011231117A (ja) 2003-10-28 2011-06-14 Ｆｉｓｃｈｅｒ−ｆｉｎｋ型合成および続くアシル化による４，５−ジアルキル−３−アシル−ピロール−２−カルボン酸誘導体の製造

Country Status (11)

Country Link
US (2) US7250520B2 (enExample)
EP (1) EP1678134B1 (enExample)
JP (2) JP4942485B2 (enExample)
KR (1) KR20060122872A (enExample)
CN (1) CN1894211A (enExample)
AT (1) ATE442355T1 (enExample)
AU (1) AU2004285972A1 (enExample)
DE (1) DE602004023105D1 (enExample)
ES (1) ES2330944T3 (enExample)
IL (1) IL175253A0 (enExample)
WO (1) WO2005042484A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9923296B2 (en) 2013-09-09 2018-03-20 Tyco Electronics Japan G.K. Electric connector terminal secured in a connector housing and electric connector

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79749C2 (en) 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AU2007217355B2 (en) 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
EP2194039A1 (en) 2006-03-16 2010-06-09 Vertex Pharmceuticals Incorporated Process for preparing optically enriched compounds
CA2679312A1 (en) 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CN101903392A (zh) 2007-02-27 2010-12-01 弗特克斯药品有限公司 丝氨酸蛋白酶的抑制剂
WO2009032198A1 (en) 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
EP2489346A1 (en) 2011-01-26 2012-08-22 NanotecMARIN GmbH Food supplement and injectable material for prophylaxis and therapy of osteoporosis and other bone diseases
US10207974B1 (en) 2017-12-05 2019-02-19 Chevron Phillips Chemical Company Lp Synthesis of gamma dicarbonyl and pyrrole compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2481369C (en) 2002-04-11 2012-07-10 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
TW200510391A (en) * 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9923296B2 (en) 2013-09-09 2018-03-20 Tyco Electronics Japan G.K. Electric connector terminal secured in a connector housing and electric connector

Also Published As

Publication number Publication date
US7250520B2 (en) 2007-07-31
AU2004285972A1 (en) 2005-05-12
DE602004023105D1 (de) 2009-10-22
ES2330944T3 (es) 2009-12-17
JP2007509991A (ja) 2007-04-19
CN1894211A (zh) 2007-01-10
HK1092134A1 (en) 2007-02-02
WO2005042484A1 (en) 2005-05-12
US20050143585A1 (en) 2005-06-30
IL175253A0 (en) 2006-09-05
EP1678134A1 (en) 2006-07-12
EP1678134B1 (en) 2009-09-09
US20080167480A1 (en) 2008-07-10
JP2011231117A (ja) 2011-11-17
ATE442355T1 (de) 2009-09-15
KR20060122872A (ko) 2006-11-30

Similar Documents

Publication Publication Date Title
JP2011231117A (ja) Ｆｉｓｃｈｅｒ−ｆｉｎｋ型合成および続くアシル化による４，５−ジアルキル−３−アシル−ピロール−２−カルボン酸誘導体の製造
JP6506836B2 (ja) Ｂ型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン
JP4558314B2 (ja) ウイルスポリメラーゼインヒビター
US7365092B2 (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
JP4460570B2 (ja) ウイルスポリメラーゼ抑制剤
US20080200497A1 (en) Hepatitis C Inhibitor Peptide Analogs
CA2369970A1 (en) Hepatitis c inhibitor tri-peptides
CN114805316B (zh) 二酮氮杂环化合物或其可药用的盐、互变异构体及其制备方法、药物组合物及应用
CN103387601B (zh) 抗登革热病毒(denv)杂环肽类化合物及其制备方法和用途
US6878727B2 (en) Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2015124064A1 (zh) 作为丙肝病毒抑制剂的噻吩或其变体衍生物及其制药用途
CA2370400A1 (en) Hepatitis c inhibitor tri-peptides
US8076365B2 (en) Viral polymerase inhibitors
HK1092134B (en) Preparation of 4,5-dialkyl-3-acyl-pyrrole-2-carboxylic acid derivatives by fischer-fink type synthesis and subsequent acylation
AU2011265547A1 (en) Preparation of 4,5-Dialkyl-3-Acyl-Pyrrole-2-Carboxylic Acid Derivatives by Fischer-Fink Type Synthesis and Subsequent Acylation
CN104926712B (zh) 合成特拉匹韦的中间体及其制备方法
WO2000053589A1 (en) Process for preparing oxazole derivatives
CN116648240A (zh) 一种环肽类病毒蛋白酶抑制剂，其制备方法，及其在抗病毒药物中的应用
CN116355044A (zh) 一类酰胺类化合物、制备方法及其应用
CN104926831A (zh) 合成特拉匹韦的中间体及其制备方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110314

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110322

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110414

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110516

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111004

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111104

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120131

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120228

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150309

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees